The pharmaceutical company BeOne Medicines joins the clinical trial MATRIX-RARE

‍

The MATRIX-RARE clinical trial is designed for patients with rare and hard-to-treat cancer types, and the first patient was enrolled in March 2025. Patients can benefit from advanced molecular diagnostics through InPreD, and currently, a total of 16 patients have been included in the trial.

BeOne Medicines has officially signed an agreement with MATRIX-RARE, enabling the administration of the PD-1 inhibitor Tislelizumab to patients. This agreement marks a significant milestone for MATRIX-RARE, as it opens up opportunities for immunotherapy for patients with rare cancers who otherwise would have limited options.

This is milestone forMATRIX-RARE, and we are thrilled about this partnership. It offers a significant opportunity for some of our patients and will contribute to valuable new insights,” says Åslaug Helland, the Principal Investigator of the study.

We are incredibly pleased to be involved in helping to develop treatment for patients with rare cancers. This is a treatment option that would otherwise not have been available. We are also grateful to be a small part of innovative initiatives such as MATRIX-RARE, says Astrid Ottosson Wadlund, Medical Director Nordic Countries for BeOne Medicines.

‍